Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927888 | 0.79 | CYP19A1 (0.50) | TBXAS1CYP19A1AGTR2CYP11B1CYP11B2 | |
| SCHEMBL5927767 | 0.76 | JAK2 (0.54) | TBXAS1CYP19A1AGTR2CYP11B1CYP11B2 | |
| SCHEMBL4489642 | 0.72 | JAK2 (0.45) | TBXAS1CYP19A1AGTR2CYP11B1CYP11B2 | |
| SCHEMBL5927242 | 0.71 | POLB (0.50) | TBXAS1CYP19A1CYP11B1CYP11B2ADRA2C | |
| SCHEMBL3760646 | 0.70 | HPGD (0.36) | — | |
| SCHEMBL13604610 | 0.69 | JAK2 (0.49) | TBXAS1CYP19A1AGTR2CYP11B1CYP11B2 | |
| SCHEMBL13604611 | 0.69 | JAK2 (0.49) | TBXAS1CYP19A1AGTR2CYP11B1CYP11B2 | |
| SCHEMBL4486676 | 0.69 | AGTR2 (0.52) | TBXAS1CYP19A1AGTR2CYP11B1CYP11B2 | |
| SCHEMBL5927840 | 0.69 | PTPRB (0.43) | TBXAS1CYP19A1AGTR2CYP11B1CYP11B2 | |
| SCHEMBL5927812 | 0.69 | PTPRB (0.43) | TBXAS1CYP19A1AGTR2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1833481-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION | 2006-09-21 | — | — | US | disclosed |
| WO-2006065794-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | FNTB, FNTA, FDPS | TBXAS1 548/4885CYP19A1 1019/4885AGTR2 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.